Compare Heron Therapeutics Inc (HRTX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs NEOS S&P 500 High Income ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while NEOS S&P 500 High Income ETF trades at $53.43. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | SPYI | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.96 | $54.07 |
52-Week Low | $0.39 | $47.98 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
SPYI, the NEOS S&P 500 High Income ETF, trades at $53.01, down 0.11% on the day. The technical outlook is bearish based on moving averages, with neutral oscillators. The fund has surpassed $10 billion in assets under management and delivers consistent monthly distributions, with a yield around 12%. Recent news highlights its appeal for income-focused investors seeking S&P 500 exposure with lower volatility.
The outlook for SPYI is supported by strong investor demand for high-yield income solutions, though the bearish technical signal and reliance on options strategies present risks. The fund's ability to generate income without significant NAV erosion remains a key advantage in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
